Actively Recruiting
Study of Selinexor, Pegaspargase, and Dexamethasone for Treating Early Stage III NKT-Cell Lymphoma
Led by Mingzhi Zhang · Updated on 2025-07-14
50
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effectiveness and safety of a combination treatment using Selinexor, Pegaspargase, and Dexamethasone for patients with early-stage NKT-cell lymphoma. The study is designed as a Phase 1 and Phase 2 clinical trial and focuses on improving local disease control and overall prognosis in this specific type of lymphoma. Patients receive an oral regimen combining Selinexor, Pegaspargase, and Dexamethasone. Selinexor works by inhibiting nuclear export proteins that are overexpressed in malignant tumor cells, including viral mRNA such as EBV. This treatment is combined with sequential radiotherapy to potentially enhance outcomes. The study monitors the responses to this combined therapy in early-stage lymphoma. Participants will be involved in regular assessments to track tumor response and overall health. The primary outcome measured is the complete response rate CRR based on tumor volume reduction, evaluated up to 36 months from randomization. Safety and treatment effects will be closely monitored during the trial period, which runs from September 2024 through December 2026.
CONDITIONS
Brief Title
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Research Team
Z
Zhang Mingzhi Mingzhi Zhang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here